

taking into account their views and potential risks and benefits of treatment options. Production of evidence-based patient information aimed at facilitating discussion and assisting an informed choice might be one way forward. As for increasing training exposure, consultants of today need to start considering the older antipsychotics as viable treatment options.

Funding

G.M.K. was supported by a clinical research fellowship grant from the Wellcome Trust (094790/Z/10/Z; 2010–13). P.B.J. has received research grants from the Wellcome Trust (095844/Z/11/Z & 088869/Z/09/Z) and the NIHR (RP-PG-0606-1335).

Acknowledgements

We thank trainees for taking part in the survey and Dr Stephen Jones, core programme director for NSFT, and Rosie Peck, postgraduate medical training administrator, for their help with the survey.

About the authors

Claire R. M. Dibben is a consultant psychiatrist, Norfolk and Suffolk NHS Foundation Trust, Norwich, UK. **Golam M. Khandaker** is a clinical lecturer, Department of Psychiatry, University of Cambridge, and Cambridgeshire and Peterborough NHS Foundation Trust. **Benjamin R. Underwood** is a consultant psychiatrist and **Christopher O'Loughlin** is a consultant psychiatrist, Cambridgeshire and Peterborough NHS Foundation Trust. **Catherine Keep** is a consultant psychiatrist, Norfolk and Suffolk NHS Foundation Trust, Norwich. **Louisa Mann** is a consultant psychiatrist, Cambridgeshire and Peterborough NHS Foundation Trust, and **Peter B. Jones** is Professor of Psychiatry, Department of Psychiatry, University of Cambridge, Deputy Head of University of Cambridge School of Clinical Medicine, and an honorary consultant psychiatrist, Cambridgeshire and Peterborough NHS Foundation Trust.

References

- 1 Bret P, Bret MC, Queuille E. Prescribing patterns of antipsychotics in 13 French psychiatric hospitals [in French]. *L'Encephale* 2009; **35**: 129–38.

- 2 Koranek AM, Smith TL, Mican LM, Rascati KL. Impact of the CATIE trial on antipsychotic prescribing patterns at a state psychiatric facility. *Schizophr Res* 2012; **137**: 137–40.
- 3 Park SC, Lee MS, Kang SG, Lee SH. Patterns of antipsychotic prescription to patients with schizophrenia in Korea: results from the health insurance review and assessment service – national patient sample. *J Korean Med Sci* 2014; **29**: 719–28.
- 4 Jauhar S, Guloksuz S, Andlauer O, Lydall G, Marques JG, Mendonca L, et al. Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence? *BMC Psychiatry* 2012; **12**: 27.
- 5 Cheng F, Jones PB. Drug treatments for schizophrenia: pragmatism in trial design shows lack of progress in drug design. *Epidemiol Psychiatr Sci* 2013; **22**: 223–33.
- 6 Underwood BR. Dominance of second-generation antipsychotics – time for reflection? *Psychiatr Bull* 2007; **31**: 233.
- 7 Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CULASS 1). *Arch Gen Psychiatry* 2006; **63**: 1079–87.
- 8 Lewis S, Lieberman J. CATIE and CULASS: can we handle the truth? *Br J Psychiatry* 2008; **192**: 161–3.
- 9 Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med* 2005; **353**: 1209–23.
- 10 Peluso MJ, Lewis SW, Barnes TR, Jones PB. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs. *Br J Psychiatry* 2012; **200**: 387–92.
- 11 National Institute for Health and Care Excellence. *Psychosis and Schizophrenia: Treatment and Management* (CG178). NICE, 2014.
- 12 Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D₁ and D₂ dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. *Arch Gen Psychiatry* 1992; **49**: 538–44.
- 13 Owens DC. Meet the relatives: a reintroduction to the clinical pharmacology of 'typical' antipsychotics (Part 2). *Adv Psychiatr Treat* 2012; **18**: 337–50.
- 14 Karthik MS, Warikoo N, Chakrabarti S, Grover S, Kulhara P. Attitudes towards antipsychotics among patients with schizophrenia on first- or second-generation medications. *Indian J Psychol Med* 2014; **36**: 288–93.

